Pyrimidine derivatives useful as inhibitors of PKC-theta

US7550473B2 · kind B2 · utility

Assignees

• Boehringer Ingelheim Pharmaceuticals, Inc. · US
• BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG · DE

Inventors

• Mario Cardozo · San Francisco, US
• Derek Cogan · Sandy Hook, US
• Charles Cywin · Bethel, US
• George Dahmann · Biberach an der Riß, DE
• Darren DiSalvo · New Milford, US
• John David Ginn · New Milford, US
• Anthony S. Prokopowicz · Stormville, US
• Denice Spero · West Redding, US
• Erick Richard Roush Young · Danbury, US

Key dates

• Filing date: Sep 3, 2004
• Grant date: Jun 23, 2009
• Expiry date: Jun 8, 2025

Classification

• Technology area (CPC H): Electricity
• CPC primary: H10K85/351
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are novel compounds of formula (I):wherein R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.